GERMANOVA, Anna, Francesco RASPAGLIESI, Luis CHIVA, Ladislav DUŠEK, Macit ARVAS, Eric LEBLANC, Tibor LENGEYL, Violante DI DONATO, Afra ZAAL, Polat DURSUN, Ignacio ZAPARDIEL, Taner TURAN, Sergio Augusto TRIGINELLI, Sang Wun KIM, Matias JURADO, Jalid SEHOULI, Borek SEHNAL, Ladislav MASAK, Nicolae IOANID, Greta DREYER, Robert JACH, Milos MLYNCEK, Valentina CHIAPPA, Fabio MARTINELLI, Jiri SLAMA, Giorgio BOGANI, Roman KOCIAN and David CIBULA. Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial. International Journal of Gynecological Cancer. Philadelphia: Lippincott Williams & Wilkins, 2019, vol. 29, No 4, p. 711-720. ISSN 1048-891X. Available from: https://dx.doi.org/10.1136/ijgc-2019-000292.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial
Authors GERMANOVA, Anna (203 Czech Republic, guarantor), Francesco RASPAGLIESI (380 Italy), Luis CHIVA (724 Spain), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Macit ARVAS (792 Turkey), Eric LEBLANC (250 France), Tibor LENGEYL (703 Slovakia), Violante DI DONATO (380 Italy), Afra ZAAL (528 Netherlands), Polat DURSUN (792 Turkey), Ignacio ZAPARDIEL (724 Spain), Taner TURAN (792 Turkey), Sergio Augusto TRIGINELLI (76 Brazil), Sang Wun KIM (410 Republic of Korea), Matias JURADO (724 Spain), Jalid SEHOULI (276 Germany), Borek SEHNAL (203 Czech Republic), Ladislav MASAK (703 Slovakia), Nicolae IOANID (642 Romania), Greta DREYER (710 South Africa), Robert JACH (616 Poland), Milos MLYNCEK (703 Slovakia), Valentina CHIAPPA (380 Italy), Fabio MARTINELLI (380 Italy), Jiri SLAMA (203 Czech Republic), Giorgio BOGANI (380 Italy), Roman KOCIAN (203 Czech Republic) and David CIBULA (203 Czech Republic).
Edition International Journal of Gynecological Cancer, Philadelphia, Lippincott Williams & Wilkins, 2019, 1048-891X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.095
RIV identification code RIV/00216224:14110/19:00110182
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1136/ijgc-2019-000292
UT WoS 000469455500009
Keywords in English uterine cancer
Tags 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 11/5/2020 09:44.
Abstract
Objectives To assess the survival of patients who have received an operation for recurrent cervical and endometrial cancer and to determine prognostic variables for improved oncologic outcome. Methods A retrospective multicenter analysis of the medical records of 518 patients with cervical (N = 288) or endometrial cancer (N = 230) who underwent surgery for disease recurrence and who had completed at least 1 year of follow-up. Results The median survival reached 57 months for patients with cervical cancer and 113 months for patients with endometrial cancer after surgical treatment of recurrence (p = 0.036). Histological sub-type had a significant impact on overall survival, with the best outcome in endometrial endometrioid cancer (121 months), followed by cervical squamous cell carcinoma, cervical adenocarcinoma, or other types of endometrial cancer (81 vs 35 vs 35 months; p<0.001). The site of recurrence did not significantly influence survival in cervical or in endometrial cancer. Cancer stage at first diagnosis, tumor grade, lymph node status at recurrence, progression-free interval after first diagnosis, and free resection margins were associated with improved overall survival on univariate analysis. On multivariate analysis, the stage at first diagnosis and resection margins were significant independent predictive parameters of an improved oncologic outcome. Conclusion Long-term survival can be achieved via secondary cytoreductive surgery in selected patients with recurrent cervical and endometrial cancer. An excellent outcome is possible even if the recurrence site is located in the lymph nodes. The possibility of achieving complete resection should be the main criterion for patient selection.
PrintDisplayed: 24/7/2024 12:16